Infections Caused by ESbL-Producing Enterobacteriaceae in Italy
NCT ID: NCT00404625
Last Updated: 2006-11-29
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
UNKNOWN
Total Enrollment
813 participants
Study Classification
OBSERVATIONAL
Study Start Date
2006-10-31
Study Completion Date
2006-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
To assess the molecular epidemiology, clinical impact, treatment outcome and risk factors for infections caused by Enterobacteriaceae producing ESBLs in Italy in a large multicenter observational survey.
SPECIFIC OBJECTIVES
1. To collect consecutive nonreplicate isolates of Enterobacteriaceae resistant to expanded-spectrum cephalosporins from clinical specimens from inpatients and outpatients.
2. To characterize the isolates for resistance phenotypes and for β-lactam resistance mechanisms.
3. To investigate the clonality of isolates.
4. To analyse the epidemiology of various resistance mechanisms/resistant clones.
5. To collect clinical and epidemiological data for patients with infections caused by the ESBL producers.
6. To analyse the epidemiology, risk factors and outcome for infections caused by ESBL producers.
SPECIFIC OBJECTIVES
1. To collect consecutive nonreplicate isolates of Enterobacteriaceae resistant to expanded-spectrum cephalosporins from clinical specimens from inpatients and outpatients.
2. To characterize the isolates for resistance phenotypes and for β-lactam resistance mechanisms.
3. To investigate the clonality of isolates.
4. To analyse the epidemiology of various resistance mechanisms/resistant clones.
5. To collect clinical and epidemiological data for patients with infections caused by the ESBL producers.
6. To analyse the epidemiology, risk factors and outcome for infections caused by ESBL producers.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
RESEARCH PLAN AND METHODOLOGY
Population All patients with infections (i.e. bacteremia, pneumonia, abdomen infections, skin infections, and urinary tract infections) caused by ESBL-producing Enterobacteriaceae.
Exclusion criteria Children \< 16 years
Trial design Multicenter prospective cohort study. Patients corresponding to the study definition will be detected by daily inspection of microbiological databases by one dedicated physician. Epidemiological variables will be detected for all patients at study admission. To identify the risk factors for infections (i.e. bacteremia, pneumonia, abdomen infections, skin infections, and urinary tract infections) caused by ESBL-producing Enterobacteriaceae a case-control study will be performed. A case patient will be defined as adult patient ( 16 years of age) who has an infection caused by ESBL-producing Enterobacteriaceae according to the definitions of the Center for Diseases Control and Prevention in Atlanta (CDC). In the Clinical Microbiology Laboratories, definition of ESBL production by the Clinical Microbiology Laboratories will be according to the CLSI guidelines (3), or to the BSAC guidelines (http://www.bsac.org.uk) for species other than Klebsiella spp., E. coli and Proteus mirabilis. One control will be selected for each case. Control will be chosen among all adult patients admitted to the same hospital during the same period (within 30 days) and in whom ESBL-producing Enterobacteriaceae were not isolated during their hospital stay. If more than one control will be available per case, patients with the date and time of admission closest to the case will be chosen.
To identify the risk factors for mortality a second case-control study will be performed comparing infected patients who died to infected patients who survived (evaluable in patients with bacteremia, wound infections, pneumonia, and meningitis, only). This analysis will be performed adjusting the results for inadequate empiric antimicrobial therapy and site of infection (see following definitions).
Data collection Medical records of in-patient admissions and microbiology and pharmacy databases will be reviewed. Data collected at the study enrollment will include: patient demographics, transfer from another hospital, resident of a long term facility or nursing home, previous hospitalization within one year, ambulatory status, requirement for chronic hemodialysis, presence of a central venous catheter (CVC), and ICU stay and surgical procedures in the 30 days prior to study inclusion. A composite score of co-morbid illnesses will be derived using the Charlson score. The severity of illness at presentation will be quantified using the criteria of McCabe and Jackson. Antibiotics administered during a 30-day period prior to study enrollment and for at least 48 hours will be recorded. For the risk factors analysis, oral and intravenous antibiotic exposure will be analysed by individual antibiotics and by classes, and will include penicillins, vancomycin, cephalosporins, antibiotics with predominantly anaerobic activity (metronidazole and clindamycin), aminoglycosides, quinolones, and carbapenems. Length of stay (LOS) after infection diagnosis, management of infections, timing and type of antimicrobial therapy, results of follow-up clinical cultures (if any), hematogenous complications and death will be also extracted from medical records. Microbiology records will be also reviewed for recovery of vancomycin resistant enterococci (VRE) or methicillin-resistant S. aureus (MRSA) in the 12 months prior to the study enrollment. All patients with infections caused by ESBL-producing Enterobacteriaceae will be followed up to hospital discharge or death.
Mortality will be defined as death occurring during the study hospitalization. Appropriate antimicrobial therapy will be defined as the initiation of therapy with activity against the ESBL-producing Enterobacteriaceae (according to the results of the antimicrobial susceptibility pattern of the isolate) from the day before to 2 days after the initial positive clinical culture result.
Outcomes Primary outcomes
1. Risk factors for the development of infections caused by ESBL producers bacteria;
2. Risk factors for inadequate initial antimicrobial therapy;
3. Overall mortality and 30-day mortality among patients receiving inadequate initial antimicrobial therapy (evaluable in patients with bacteremia, abdominal infections and pneumonia, only);
4. Variability by site of infection of overall mortality and 30-day mortality among patients receiving inadequate initial antimicrobial therapy (evaluable in patients with bacteremia, abdominal infections and pneumonia, only).
Secondary outcomes
1. Lenght of hospitalization;
2. Costs of inadequate initial therapy;
3. Days of defervescence.
Statistical analysis At the end of the study two different analysis will be performed: the first one will consider patients with bacteremia, abdominal infections and pneumonia, and it will be focused on mortality; the second analysis will consider all infected patients and it will be focused on risk factor analysis and secondary outcomes.
Sample size justification Assumptions
Patients with bacteremia, pneumonia, abdomen infections, skin infections and urinary tract infections (first analysis):
Mortality among patients with inadequate initial therapy: 25% Mortality among patients with appropriate initial therapy: 13%
All included patients:
Percentage of bacteremia: 20% Percentage of pneumonia: 10% Percentage of abdomen infections: 15% Percentage of skin infections: 3% Percentage of urinary tract infections: 52%
Primary outcomes Risk factors for mortality Difference of mortality between controls (inappropriate therapy) and cases (appropriate therapy): we anticipated a reduction from 25% to 13%.
Secondary outcomes Difference of length of hospitalization between cases (appropriate therapy) and controls (inappropriate therapy): we anticipated a decrease from 80% (length of hospitalization \< 15 days) to 40%.
Difference of defervescence between cases (appropriate therapy) and controls (inappropriate therapy): we anticipated a decrease from 85% (defervescence \< 3 days) to 30%.
Assuming that p1=p2, where p1 is the proportion in population 1 and p2 is the proportion in population 2 and that alpha=0.05 (two-sided), power=0.80.
Required sample size for analysis of risk factors for mortality: 366 patients with bacteremia, wound infections, pneumonia, and meningitis. To include 366 patients with the above reported infections the total sample size is likely to be 813 patients infected with ESBL-producing Enterobacteriaceae.
Microbiological analysis of bacterial strains
All ESBL-producing isolates obtained from patients included in the study at the Clinical Microbiology Laboratories of each Clinical Center will be collected and subjected to further investigation including:
* confirmation of the identification at the species level;
* determination of the antimicrobial resistance profile against a standard set of drugs;
* analysis of the ESBL determinants;
* analysis of clonal relationship between bacterial isolates of the same species. Results of microbiological analysis will be used for correlation with clinical data to assess the epidemiological and clinical impact of the ESBL-producing strains.
Experimental methodology
Confirmation of identification of the bacterial isolates at the species level will be carried out by standard phenotypic methods (10). In case of ambiguity of results, identification will be confirmed by 16S rDNA sequencing (16).
Antimicrobial susceptibility testing will be carried out by broth microdilution as recommended by the CLSI (3), and categorical assignment will be carried out using the CLSI breakpoints (3). The following agents will be included: ertapenem, imipenem, meropenem, cefepime, ceftazidime, cefotaxime, piperacillin/tazobactam, amoxicillin/clavulanate, ciprofloxacin, levofloxacin, gentamicin, amikacin.
The nature of the ESBL determinants will be investigated by molecular analysis using PCR and sequencing, as described previously (9, 15). The presence of ESBL determinants of the TEM-, SHV, CTX-M- and PER-type (i. e. those known to be circulating in Italy (9, 15)) will be investigated. In case of negative results with the available probes, the ESBL phenotype will be reconfirmed and, if positive, the nature of -lactamase deerminants will be studied by means of: (i) analytical isoelectric focusing (IEF) on crude extracts using previously described methods (14); (ii) DNA microarray technology, using a microarray for β-lactamase genes that has been developed in our laboratory, which includes probes for uncommon ESBL genes such as VEB, GES, BES, SFO, and TLA enzymes. In case of new ESBL genes undetected by the above methods (an unlikely occurrence), In the case of production of ESBL but unaccounted for by the presence of known resistance determinants, the resistance determinants will be studied by means of a shotgun-cloning approach followed by mapping and sequencing.
Clonal relatedness among isolates of the same species will be investigated by high-throughput genotyping techniques such as RAPD (Random Amplified Polymorphic DNA) and/or by AFLP (Amplified Fragment Length Polymorphism) analysis and/or REP PCR (19-21). In selected isolates, the clonal relationships will be performed by macrorestriction analysis of genomic DNA by pulsed-field gel electrophoresis (PFGE).
Plasmid analysis and investigation of resistance determinants to non β-lactam agents (by molecular techniques) will be considered in selected cases, should these information be relevant for correlation with clinical and epidemiological data.
Population All patients with infections (i.e. bacteremia, pneumonia, abdomen infections, skin infections, and urinary tract infections) caused by ESBL-producing Enterobacteriaceae.
Exclusion criteria Children \< 16 years
Trial design Multicenter prospective cohort study. Patients corresponding to the study definition will be detected by daily inspection of microbiological databases by one dedicated physician. Epidemiological variables will be detected for all patients at study admission. To identify the risk factors for infections (i.e. bacteremia, pneumonia, abdomen infections, skin infections, and urinary tract infections) caused by ESBL-producing Enterobacteriaceae a case-control study will be performed. A case patient will be defined as adult patient ( 16 years of age) who has an infection caused by ESBL-producing Enterobacteriaceae according to the definitions of the Center for Diseases Control and Prevention in Atlanta (CDC). In the Clinical Microbiology Laboratories, definition of ESBL production by the Clinical Microbiology Laboratories will be according to the CLSI guidelines (3), or to the BSAC guidelines (http://www.bsac.org.uk) for species other than Klebsiella spp., E. coli and Proteus mirabilis. One control will be selected for each case. Control will be chosen among all adult patients admitted to the same hospital during the same period (within 30 days) and in whom ESBL-producing Enterobacteriaceae were not isolated during their hospital stay. If more than one control will be available per case, patients with the date and time of admission closest to the case will be chosen.
To identify the risk factors for mortality a second case-control study will be performed comparing infected patients who died to infected patients who survived (evaluable in patients with bacteremia, wound infections, pneumonia, and meningitis, only). This analysis will be performed adjusting the results for inadequate empiric antimicrobial therapy and site of infection (see following definitions).
Data collection Medical records of in-patient admissions and microbiology and pharmacy databases will be reviewed. Data collected at the study enrollment will include: patient demographics, transfer from another hospital, resident of a long term facility or nursing home, previous hospitalization within one year, ambulatory status, requirement for chronic hemodialysis, presence of a central venous catheter (CVC), and ICU stay and surgical procedures in the 30 days prior to study inclusion. A composite score of co-morbid illnesses will be derived using the Charlson score. The severity of illness at presentation will be quantified using the criteria of McCabe and Jackson. Antibiotics administered during a 30-day period prior to study enrollment and for at least 48 hours will be recorded. For the risk factors analysis, oral and intravenous antibiotic exposure will be analysed by individual antibiotics and by classes, and will include penicillins, vancomycin, cephalosporins, antibiotics with predominantly anaerobic activity (metronidazole and clindamycin), aminoglycosides, quinolones, and carbapenems. Length of stay (LOS) after infection diagnosis, management of infections, timing and type of antimicrobial therapy, results of follow-up clinical cultures (if any), hematogenous complications and death will be also extracted from medical records. Microbiology records will be also reviewed for recovery of vancomycin resistant enterococci (VRE) or methicillin-resistant S. aureus (MRSA) in the 12 months prior to the study enrollment. All patients with infections caused by ESBL-producing Enterobacteriaceae will be followed up to hospital discharge or death.
Mortality will be defined as death occurring during the study hospitalization. Appropriate antimicrobial therapy will be defined as the initiation of therapy with activity against the ESBL-producing Enterobacteriaceae (according to the results of the antimicrobial susceptibility pattern of the isolate) from the day before to 2 days after the initial positive clinical culture result.
Outcomes Primary outcomes
1. Risk factors for the development of infections caused by ESBL producers bacteria;
2. Risk factors for inadequate initial antimicrobial therapy;
3. Overall mortality and 30-day mortality among patients receiving inadequate initial antimicrobial therapy (evaluable in patients with bacteremia, abdominal infections and pneumonia, only);
4. Variability by site of infection of overall mortality and 30-day mortality among patients receiving inadequate initial antimicrobial therapy (evaluable in patients with bacteremia, abdominal infections and pneumonia, only).
Secondary outcomes
1. Lenght of hospitalization;
2. Costs of inadequate initial therapy;
3. Days of defervescence.
Statistical analysis At the end of the study two different analysis will be performed: the first one will consider patients with bacteremia, abdominal infections and pneumonia, and it will be focused on mortality; the second analysis will consider all infected patients and it will be focused on risk factor analysis and secondary outcomes.
Sample size justification Assumptions
Patients with bacteremia, pneumonia, abdomen infections, skin infections and urinary tract infections (first analysis):
Mortality among patients with inadequate initial therapy: 25% Mortality among patients with appropriate initial therapy: 13%
All included patients:
Percentage of bacteremia: 20% Percentage of pneumonia: 10% Percentage of abdomen infections: 15% Percentage of skin infections: 3% Percentage of urinary tract infections: 52%
Primary outcomes Risk factors for mortality Difference of mortality between controls (inappropriate therapy) and cases (appropriate therapy): we anticipated a reduction from 25% to 13%.
Secondary outcomes Difference of length of hospitalization between cases (appropriate therapy) and controls (inappropriate therapy): we anticipated a decrease from 80% (length of hospitalization \< 15 days) to 40%.
Difference of defervescence between cases (appropriate therapy) and controls (inappropriate therapy): we anticipated a decrease from 85% (defervescence \< 3 days) to 30%.
Assuming that p1=p2, where p1 is the proportion in population 1 and p2 is the proportion in population 2 and that alpha=0.05 (two-sided), power=0.80.
Required sample size for analysis of risk factors for mortality: 366 patients with bacteremia, wound infections, pneumonia, and meningitis. To include 366 patients with the above reported infections the total sample size is likely to be 813 patients infected with ESBL-producing Enterobacteriaceae.
Microbiological analysis of bacterial strains
All ESBL-producing isolates obtained from patients included in the study at the Clinical Microbiology Laboratories of each Clinical Center will be collected and subjected to further investigation including:
* confirmation of the identification at the species level;
* determination of the antimicrobial resistance profile against a standard set of drugs;
* analysis of the ESBL determinants;
* analysis of clonal relationship between bacterial isolates of the same species. Results of microbiological analysis will be used for correlation with clinical data to assess the epidemiological and clinical impact of the ESBL-producing strains.
Experimental methodology
Confirmation of identification of the bacterial isolates at the species level will be carried out by standard phenotypic methods (10). In case of ambiguity of results, identification will be confirmed by 16S rDNA sequencing (16).
Antimicrobial susceptibility testing will be carried out by broth microdilution as recommended by the CLSI (3), and categorical assignment will be carried out using the CLSI breakpoints (3). The following agents will be included: ertapenem, imipenem, meropenem, cefepime, ceftazidime, cefotaxime, piperacillin/tazobactam, amoxicillin/clavulanate, ciprofloxacin, levofloxacin, gentamicin, amikacin.
The nature of the ESBL determinants will be investigated by molecular analysis using PCR and sequencing, as described previously (9, 15). The presence of ESBL determinants of the TEM-, SHV, CTX-M- and PER-type (i. e. those known to be circulating in Italy (9, 15)) will be investigated. In case of negative results with the available probes, the ESBL phenotype will be reconfirmed and, if positive, the nature of -lactamase deerminants will be studied by means of: (i) analytical isoelectric focusing (IEF) on crude extracts using previously described methods (14); (ii) DNA microarray technology, using a microarray for β-lactamase genes that has been developed in our laboratory, which includes probes for uncommon ESBL genes such as VEB, GES, BES, SFO, and TLA enzymes. In case of new ESBL genes undetected by the above methods (an unlikely occurrence), In the case of production of ESBL but unaccounted for by the presence of known resistance determinants, the resistance determinants will be studied by means of a shotgun-cloning approach followed by mapping and sequencing.
Clonal relatedness among isolates of the same species will be investigated by high-throughput genotyping techniques such as RAPD (Random Amplified Polymorphic DNA) and/or by AFLP (Amplified Fragment Length Polymorphism) analysis and/or REP PCR (19-21). In selected isolates, the clonal relationships will be performed by macrorestriction analysis of genomic DNA by pulsed-field gel electrophoresis (PFGE).
Plasmid analysis and investigation of resistance determinants to non β-lactam agents (by molecular techniques) will be considered in selected cases, should these information be relevant for correlation with clinical and epidemiological data.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Enterobacteriaceae Infections
Bacteremia
Pneumonia
Skin Diseases
Urinary Tract Infections
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Bacteremia caused by ESBL-producing Enterobacteriaceae
Pneumonia caused by ESBL-producing Enterobacteriaceae
Abdomen infections due to ESBL-producing Enterobacteriaceae
Skin infections caused by ESBL-producing Enterobacteriaceae
Urinary infections due to ESBL-producing Enterobacteriaceae
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Observational Model Type
CASE_CONTROL
Study Time Perspective
OTHER
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Risk factors for infections due to ESBL+ Enterobacteriaceae
Intervention Type
BEHAVIORAL
Risk factors for inadequate initial antimicrobial therapy
Intervention Type
BEHAVIORAL
Overall and 30-day mortality in bad first antibiotic therapy
Intervention Type
BEHAVIORAL
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* All patients with infections (i.e. bacteremia, pneumonia, abdomen infections, skin infections, and urinary tract infections) caused by ESBL-producing Enterobacteriaceae
Exclusion Criteria
* Children \< 16 years
Minimum Eligible Age
16 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Merck Sharp & Dohme LLC
INDUSTRY
Sponsor Role
collaborator
University of Siena
OTHER
Sponsor Role
lead
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Gian Maria Rossolini, professore
Role: STUDY_CHAIR
Università di Siena
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Università Cattolica S. Cuore, Policlinico Gemelli
Roma, Roma, Italy
Site Status
RECRUITING
Università Politecnica delle Marche
Ancona, , Italy
Site Status
RECRUITING
A.O. "Ospedali Riuniti di Bergamo"
Bergamo, , Italy
Site Status
RECRUITING
Univeristà di Firenze, Ospedale Careggi
Florence, , Italy
Site Status
RECRUITING
Ospedale Niguarda Ca' Granda
Milan, , Italy
Site Status
RECRUITING
Università di Varese
Varese, , Italy
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
Italy
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Roberto Cauda, Professore
Role: primary
Giorgio Scalise, MD
Role: primary
Fredy Suter, MD
Role: primary
Franco Paradisi, Professore
Role: primary
Liliana Caggese, MD
Role: primary
Paolo Grossi, MD
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
Tacconelli E, Cataldo MA, Mutters NT, Carrara E, Bartoloni A, Raglio A, Cauda R, Mantengoli E, Luzzaro F, Pan A, Beccara LA, Pecile P, Tinelli M, Rossolini GM. Role of place of acquisition and inappropriate empirical antibiotic therapy on the outcome of extended-spectrum beta-lactamase-producing Enterobacteriaceae infections. Int J Antimicrob Agents. 2019 Jul;54(1):49-54. doi: 10.1016/j.ijantimicag.2019.04.007. Epub 2019 Apr 12.
Reference Type
DERIVED
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
P1908
Identifier Type: -
Identifier Source: org_study_id